Last reviewed · How we verify
Vedolizumab, Ustekinumab, or Tofacitinib
Vedolizumab, Ustekinumab, or Tofacitinib is a Small molecule drug developed by Asan Medical Center. It is currently in Phase 2 development.
At a glance
| Generic name | Vedolizumab, Ustekinumab, or Tofacitinib |
|---|---|
| Sponsor | Asan Medical Center |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Describing Treatment Patterns and Creating an Updated Treatment Flow in an Ulcerative Colitis Population
- Determination of the Optimal Treatment Target in Ulcerative Colitis (PHASE4)
- COMPARE - Pediatric Inflammatory Bowel Disease (PIBD)
- Identification of Predictive Biomarkers for Response to Biologic Therapies and Tofacitinib in Inflammatory Bowel Disease (PHASE4)
- A Study to Evaluate the Safety of Ozanimod Exposure During Pregnancy in Women With Ulcerative Colitis and Their Infants
- Comparative Effectiveness of Biologics or Small Molecule Therapies in Inflammatory Bowel Disease (IBD)
- Risk of Incident IMID in Patients Treated With Biologics and Immunosuppressive Drugs for a Single IMID
- Prediction Model for Response to Biologics and Small Molecular Agent for UC
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vedolizumab, Ustekinumab, or Tofacitinib CI brief — competitive landscape report
- Vedolizumab, Ustekinumab, or Tofacitinib updates RSS · CI watch RSS
- Asan Medical Center portfolio CI
Frequently asked questions about Vedolizumab, Ustekinumab, or Tofacitinib
What is Vedolizumab, Ustekinumab, or Tofacitinib?
Vedolizumab, Ustekinumab, or Tofacitinib is a Small molecule drug developed by Asan Medical Center.
Who makes Vedolizumab, Ustekinumab, or Tofacitinib?
Vedolizumab, Ustekinumab, or Tofacitinib is developed by Asan Medical Center (see full Asan Medical Center pipeline at /company/asan-medical-center).
What development phase is Vedolizumab, Ustekinumab, or Tofacitinib in?
Vedolizumab, Ustekinumab, or Tofacitinib is in Phase 2.